Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 155.17 USD -0.21% Market Closed
Market Cap: 373.6B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Johnson & Johnson
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Johnson & Johnson
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Johnson & Johnson
NYSE:JNJ
Other Operating Expenses
$2.2B
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
27%
Bristol-Myers Squibb Co
NYSE:BMY
Other Operating Expenses
$2B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Other Operating Expenses
$1.1B
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zoetis Inc
NYSE:ZTS
Other Operating Expenses
-$5m
CAGR 3-Years
0%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Johnson & Johnson
Glance View

Market Cap
373.5B USD
Industry
Pharmaceuticals

Johnson & Johnson, often referred to as J&J, is a global healthcare giant that operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health Products. Founded in 1886, the company has built a strong reputation for its innovative products, which range from life-saving prescription medications to everyday consumer items such as Band-Aids and Tylenol. With a commitment to improving health and well-being, J&J has consistently invested in research and development, yielding a robust pipeline of drugs and technologies that address critical health challenges, including oncology, immunology, and infectious diseases. This ongoing innovation positions the company favorably in a competitive landscape, ensuring sustained revenue growth and profitability. For investors, Johnson & Johnson represents a compelling opportunity not only due to its diversified business model but also its robust financial health. The company boasts a history of steady revenue growth, strong cash flow generation, and a reliable dividend, making it a perennial favorite for income-focused investors. While it has faced some legal challenges and market pressures, J&J’s ability to adapt and respond to these issues has underscored its resilience. With a strong balance sheet and a global footprint in the ever-growing healthcare sector, Johnson & Johnson continues to demonstrate why it is often regarded as a cornerstone investment in a well-rounded portfolio.

JNJ Intrinsic Value
159.74 USD
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Johnson & Johnson's Other Operating Expenses?
Other Operating Expenses
2.2B USD

Based on the financial report for Sep 29, 2024, Johnson & Johnson's Other Operating Expenses amounts to 2.2B USD.

What is Johnson & Johnson's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 10Y
27%

Over the last year, the Other Operating Expenses growth was 31%. The average annual Other Operating Expenses growth rates for Johnson & Johnson have been 34% over the past three years , and 27% over the past ten years .

Back to Top